Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Cancer. 2012 Jan 15;118(2):518-27. doi: 10.1002/cncr.26296. Epub 2011 Jun 29.
The reported high rate of local recurrence (LR) in myxofibrosarcoma raises the question of whether this sarcoma histology should be considered radioresistant. In this study, the authors compared rates and patterns of LR of high-grade (HG) myxofibrosarcoma with rates and patterns of HG leiomyosarcoma, which was chosen because of the similarity in incidence and general treatment approach.
Two hundred two patients with primary, nonmetastatic extremity myxofibrosarcoma (n = 114) and leiomyosarcoma (n = 88) underwent limb-sparing surgery and were followed prospectively. All 202 patients had HG tumors, and 138 patients (68%) received adjuvant radiation therapy.
The groups were comparable in terms of age, sex, and receipt of chemotherapy. Compared with leiomyosarcoma, myxofibrosarcoma presented more frequently with tumors >5 cm (P < .001), deep location (P = .036), and upper extremity site (P = .015). In addition, rates of positive/close margins (P < .001) and the receipt of radiation therapy (P < .001) were significantly higher in the myxofibrosarcoma group. The 5-year overall LR rate was not significantly different according to histology (14.6% for myxofibrosarcoma, 13.2% for leiomyosarcoma; P = .594). The only predictor of LR for the whole cohort of patients was positive/close margins (P = .01). Of 17 myxofibrosarcoma LRs, 8 (47%) occurred out of field, versus 1 of 12 (8%) leiomyosarcoma LRs (P = .04). Leiomyosarcoma more commonly recurred distantly (54.1% vs 24.3% at 5 years; P = .014).
Despite more adverse clinical features, myxofibrosarcoma recurred distantly less often than leiomyosarcoma, whereas the LR rates were comparable between the 2 groups, suggesting that adjuvant radiation therapy is effective in myxofibrosarcoma. Myxofibrosarcoma LRs more commonly occurred out of field. Reduction in radiation field margins may not be advisable in patients with myxofibrosarcoma.
黏液纤维肉瘤的局部复发率(LR)较高,这引发了一个问题,即这种肉瘤组织学是否应被认为具有放射抵抗性。在这项研究中,作者比较了高级别(HG)黏液纤维肉瘤和高级别 leiomyosarcoma 的 LR 发生率和模式,选择 leiomyosarcoma 是因为其发病率和一般治疗方法相似。
202 例原发性、非转移性肢体黏液纤维肉瘤(n = 114)和 leiomyosarcoma(n = 88)患者接受保肢手术并进行前瞻性随访。所有 202 例患者均为 HG 肿瘤,138 例(68%)接受辅助放疗。
两组在年龄、性别和化疗接受情况方面具有可比性。与 leiomyosarcoma 相比,黏液纤维肉瘤的肿瘤更大(>5 cm;P <.001)、位置更深(P =.036)、位于上肢(P =.015)。此外,黏液纤维肉瘤组的阳性/切缘近(P <.001)和放疗接受率(P <.001)显著更高。根据组织学,5 年总 LR 率无显著差异(黏液纤维肉瘤为 14.6%,leiomyosarcoma 为 13.2%;P =.594)。整个患者队列 LR 的唯一预测因子是阳性/切缘近(P =.01)。在 17 例黏液纤维肉瘤 LR 中,8 例(47%)发生于野外,而 12 例 leiomyosarcoma LR 中仅 1 例(8%)(P =.04)。leiomyosarcoma 更常远处复发(5 年时分别为 54.1%和 24.3%;P =.014)。
尽管黏液纤维肉瘤具有更多不良的临床特征,但远处复发的频率低于 leiomyosarcoma,而两组之间的 LR 率相当,表明辅助放疗对黏液纤维肉瘤有效。黏液纤维肉瘤的 LR 更常见于野外。对于黏液纤维肉瘤患者,减少放疗野边缘可能不是明智之举。